Director/PDMR Transaction

Molecule Group PLC

13 October 2026

 

Molecule Group plc

(the “Company”, “Group” or “Molecule”)

Director/PDMR Transaction

Molecule Group plc, the Company building a leading regulated UK ePharmacy through buy-and-build, announces that Brendan O’Brien, Chief Operating Officer, has acquired a total of 41,500 ordinary shares of 10 pence each in the Company ("Ordinary Shares") at an average price of £2.13 per Ordinary Share. Following the purchases, Mr O’Brien holds 591,500 Ordinary Shares, representing 2.2% of the Company’s issued share capital.

The Notification of Dealings are set out below.

The following transactions have been notified to the Company pursuant to Article 19.1(a) of the UK Market Abuse Regulation ("MAR"). This notification is issued in accordance with Article 19.3 of MAR.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name:	Brendan O’Brien
2	Reason for the notification
a)	Position/Status:	Chief Operating Officer
b)	Initial Notification/Amendment:	Initial Notification
3	Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor
a)	Name:	Molecule Group plc
b)	LEI:	213800W5TPGBRC2V7L20
4.	Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)	Description of the financial instrument:	Ordinary Shares of 10 pence each
b)	Identification code:	ISIN: GB00BTQLZH16
b)	Nature of the transaction:	Acquisition of Ordinary Shares
c)	Price(s) and volume(s):	Price Volume £2.14 18,300
d)	Aggregated volume: Price:	Single Transaction
e)	Date of the Transaction:	08-10-2026
f)	Place of the Transaction:	XLON:AIM
4.	Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted.
a)	Description of the financial instrument:	Ordinary Shares of 10 pence each
b)	Identification code:	ISIN: GB00BTQLZH16
b)	Nature of the transaction:	Acquisition of Ordinary Shares
c)	Price(s) and volume(s):	Price Volume £2.12 23,200
d)	Aggregated volume: Price:	Single Transaction
e)	Date of the Transaction:	12-10-2026
f)	Place of the Transaction:	XLON:AIM

For further information please contact:

Molecule Group plc Michael Kraftman, Chief Executive Officer Keith Butcher, Chief Finance Officer Brendan O’Brien, Chief Operating Officer investors.molecule.co.uk	Email: [e-mail]
Canaccord Genuity Limited (Nominated Adviser and Sole Broker) Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott	Tel: [phone]
Alma Strategic Communications (Financial PR) Justine James / Sam Modlin / Will Merison	Email: [e-mail] Tel: [phone]

Notes to Editors

Molecule Group plc (AIM: MOL) is building a leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.

The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit investors.molecule.co.uk

 

END